Sanegene Bio USA Inc. announced that it has received $80 million in a round of funding led by Tencent and YuanBio on December 1, 2023. The transaction included participation from new investors Northern light venture capital, Suzhou Oriza Holdings Co., Ltd., Shenzhen Capital Group Co., Ltd., Xiamen C&D Inc. (SHSE:600153), existing investor Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, TF Capital, K2VC and Beijing Yahui Asset Management Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10 CNY | +1.32% | -0.60% | +3.84% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.84% | 4.15B | |
+56.60% | 91.85B | |
+41.92% | 71.52B | |
+19.61% | 63.05B | |
+27.08% | 30.34B | |
+21.43% | 28.92B | |
+16.39% | 21.62B | |
+16.68% | 17.92B | |
-3.76% | 12.84B | |
+2.43% | 5.92B |
- Stock Market
- Equities
- 600153 Stock
- News Xiamen C&D Inc.
- Sanegene Bio USA Inc. announced that it has received $80 million in funding from a group of investors